Warner Chilcott Company, LLC v. Teva Pharmaceuticals USA, Inc., No. 14-1439 (Fed. Cir. Nov. 18, 2014)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

In these consolidated appeals, Warner Chilcott Co m- pany, LLC (“Warner”) and Hoffmann- La Roche Inc. (“Roche”) (collectively, the “Plaintiffs”) appeal from the decision of the United States District Court for the Dis- trict of Delaware granting summary judgment that claims 6, 8, 9, and 13– 15 of U.S. Patent 7,192,938 (the “’938 patent”) and claims 9 and 10 of U.S. Patent 7,718,634 (the “’634 patent”) (collectively, “the asserted claims”) were invalid for obviousness . Se e Warner Chilcott Co. v. Teva Pharm. USA, Inc. , __ F. Supp. 2d __, No.